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Abstract: Cyanopeptolins (CPs) are one of the most frequently occurring cyanobacterial peptides,
many of which are inhibitors of serine proteases. Some CP variants are also acutely toxic to aquatic
organisms, especially small crustaceans. In this study, thirteen CPs, including twelve new variants,
were detected in the cyanobacterium Nostoc edaphicum CCNP1411 isolated from the Gulf of Gdan´sk
(southern Baltic Sea). Structural elucidation was performed by tandem mass spectrometry with
verification by NMR for CP962 and CP985. Trypsin and chymotrypsin inhibition assays confirmed
the significance of the residue adjacent to 3-amino-6-hydroxy-2-piperidone (Ahp) for the activity of
the peptides. Arginine-containing CPs (CPs-Arg2) inhibited trypsin at low IC50 values (0.24–0.26 µM)
and showed mild activity against chymotrypsin (IC50 3.1–3.8 µM), while tyrosine-containing CPs
(CPs-Tyr2) were selectively and potently active against chymotrypsin (IC50 0.26 µM). No degradation
of the peptides was observed during the enzyme assays. Neither of the CPs were active against
thrombin, elastase or protein phosphatase 1. Two CPs (CP962 and CP985) had no cytotoxic effects on
MCF-7 breast cancer cells. Strong and selective activity of the new cyanopeptolin variants makes them
potential candidates for the development of drugs against metabolic disorders and other diseases.
Keywords: cyanobacteria; Nostoc; cyanopeptolins; protease inhibitors
1. Introduction
Cyanobacterial peptides belong to the most interesting group of natural bioactive products.
Initially, they were recognized as hepatotoxic and inflammatory agents. In the late 1970s, the therapeutic
potential of the compounds attracted the attention of the scientific community [1,2]. Since then,
numerous and structurally diverse cyanopeptides have been identified, including potent anticancer
agents such as dolastatin 10, cryptophycin 52, largazol, and apratoxin [3–7]. Cyanopeptides have also
been recognized as potent inhibitors of key metabolic enzymes, targeting mainly serine proteases and
protein phosphatases [7–9]. Among these compounds, cyanopeptolins (CPs), a large family of cyclic
depsipeptides (peptidolactones), are commonly produced by different cyanobacterial genera, including
Microcystis, Planktothrix, Anabaena and Nostoc. These nonribosomal peptides (NRPs) are composed
Mar. Drugs 2018, 16, 220; doi:10.3390/md16070220 www.mdpi.com/journal/marinedrugs
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of a six-amino acid ring and a side chain with one or two residues. All CPs are characterized by the
presence of 3-amino-6-hydroxy-2-piperidone (Ahp) in position 3 (Figures 1 and 2). In a few CP-type
peptides, the occurrence of O-methylated Ahp (Amp) in this position has been reported [10–12]. Ahp
is also present in other cyclodepsipeptides such as aeruginopeptins, micropeptins, microcystilide,
nostopeptins, and oscillapeptins. Position 1 in CP-type peptides is conserved and occupied by
L-threonine with β-hydroxy group linked by an ester bond to carboxy terminus of amino acid in
position 6 (i.e., Val, Ile or allo-Ile). Position 2 is most variable and occupied by residues differing in
structure and polarity (e.g., Arg, Leu, Gln, Tyr, Phe, MeTyr, H4Tyr, Dhb) [13]. In position 4, Leu/Ile,
Phe or Thr can be found, while in position 5, N-methylated aromatic amino acids, N-MeTyr or
MePhe, or their homo-variants are usually present. In some CPs, Tyr or N-MeTyr were modified
by chlorination [14]. The side chain is attached via the amino group on Thr. Usually, two major
types of side chains were reported: with 1–2 amino acid residues (e.g., Asp, Glu) and aliphatic
fatty acid of variable length or with glyceric acid directly linked to Thr or to an amino acid side
chain [15–17]. Glyceric acid can be modified by sulfation or/and O-methylation [11,18]. In the side
chain of aeruginopeptins, micropeptins or microcystilide, a hydroxyphenyl lactic acid (Hpla) was
reported [19–21].
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Cyanopeptolins, like other nonribosomal peptides, are synthesized on large multi-enzyme
complexes with modular structure. The general organization of the gene clusters encoding the enzymes
in different cyanobacteria is similar, however, some differences in the specificity of adenylation
domains and in the presence of tailoring domains exist [22–24]. In the CP gene cluster from
Microcystis and Anabaena, a halogenase gene was present [23,24], whereas in Planktothrix a glyceric
acid-activating domain and sulfotransferase domain occurred [22]. The modifications in gene clusters
and differences in substrate specificity of adenylation domains result in intra- and interspecies diversity
of CP structures.
The majority of CPs showed inhibitory activity against serine proteases, such as trypsin,
chymotrypsin, thrombin, and elastase (e.g., [12,25–30]). Cyanopeptolins with one (CP S) or two
sulphate groups (CP SS) also inhibited plasmin [18]. The activity of the peptides was found to be
determined by the residue in position 2, however, the significance of other structural elements was
also reported [12]. In ichthyopeptins, CP analogues with 2-hydroxy-3-(4′-hydroxyphenyl)lactic acid
(PAA) in the side chain, strong antiviral activity against influenza A virus was observed [31]. Tests
on small crustaceans revealed the harmful effects of Ahp-containing cyclic depsipeptides [16,32,33].
For CP SS, the toxicity against Daphnia magna was even higher than for microcystin-LR [10], the most
widely studied cyanobacterial toxin.
In cyanobacterial strains from the Nostoc genus, typical CP variants produced by Microcystis have
not been reported. However, several other CP-type structures, namely nostopeptins, insulapeptolides,
and nostocyclins were identified (Table 1) [34–38]. Nostopeptin A and B from N. minutum NIES-26,
with 3-hydroxy-4-methylproline (Hmp) in position 1, showed inhibitory activity against elastase and
chymotrypsin, but were inactive against papain, trypsin, thrombin, and plasmin [35]. Insulapeptolides
A–D from N. insulare are characterized by the presence of Hmp in position 1 and citrulline (Cit) in
the side chain. Extracts containing these peptides potently and selectively inhibited human leukocyte
elastase (HLE) [38]. Nostocyclin from Nostoc sp. DUN901 has D-Hpla in the side chain and two
homoserine residues (Hse): one in a ring part and one in a side chain of the molecule [34]. The peptide
was not toxic in mouse bioassay, but showed weak activity against protein phosphatases [34,39].
Among cyanobacterial strains from the same species, significant differences in the peptide profiles
are frequently reported. In our study, the structures of CPs produced by N. edaphicum CCNP1411
isolated from coastal waters of the Gulf of Gdan´sk, southern Baltic Sea, were elucidated. In total,
thirteen CP variants were identified. They represent structures typical of CPs from Microcystis,
but different from CP-type peptides previously found in other Nostoc strains. The biological activity
of the peptides against serine proteases, protein phosphatase 1, and MCF-7 breast cancer cells
were assessed.
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Table 1. Cyanopeptolin-type peptides identified in cyanobacteria from Nostoc genus.
Molecular Mass Peptide Name Structure Enzyme Inhibition References
921 Nostopeptin BN920 [Thr+Leu+Ahp 1 +Phe+MeTyr+Val]Gln+Ac 2
Chymotrypsin
(IC50 0.11 µM)
[36]
926 Nostopeptin B [Hmp 3 +Leu+Ahp+Ile+MeTyr+Ile]Gln+Ac
Elastase
(IC50 11.0 µg/mL)
Chymotrypsin
(IC50 1.6 µg/mL)
[35]
937 Nostopeptin A [Hmp+Leu+Ahp+Ile+MeTyr+Ile]Gln+BA 4
Elastase
(IC50 1.3 µg/mL)
Chymotrypsin
(IC50 1.4 µg/mL)
[35]
942 Insulapeptolide A [Hmp+Leu+Ahp+Ile+MeTyr+Val]Cit 5 +Ac HLE 10 (IC50 0.14 µM) *
[38]
956 Insulapeptolide B [Hmp+Leu+Ahp+Leu+MeTyr+Ile]Cit+Ac HLE (IC50 0.10 µM) *
956 Insulapeptolide C [Hmp+Leu+Ahp+Ile+diMeTyr 6 +Val]Cit+Ac HLE (IC50 0.090 µM) *
970 Insulapeptolide D [Hmp+Leu+Ahp+Ile+diMeTyr+Ile]Cit+Ac HLE (IC50 0.085 µM) *
991 Insulapeptolide G [Thr+Hph 7 +Ahp+Thr+MePhe+Val]Ser+Pro+BA HLE (IC50 3.5 µM) *
1005 Insulapeptolide H [Thr+Hph+Ahp+Thr+MeTyr+Ile]Ser+Pro+BA HLE (IC50 2.7µM) *
1007 Insulapeptolide F [Thr+Hph+Ahp+Thr+MeTyr+Val]Ser+Pro+BA HLE (IC50 1.6 µM) *
1021 Insulapeptolide E [Thr+Hph+Ahp+Thr+MeTyr+Ile]Ser+Pro+BA HLE (IC50 3.2 µM) *
1116 Nostocyclin [Thr+Hse 8 +Ahp+Phe+MeTyr+Val]Hse+Ile+Hpla 9 PP1 (IC50 64.0 µM) [34]
* activity of extracts; 1 Ahp 3-amino-6-hydroxy-2-piperidone; 2 Ac acetic acid; 3 Hmp 3-hydroxy-4-methyl-proline; 4 BA butanoic acid; 5 Cit citrulline; 6 diMeTyr N,O-dimethyltyrosine;
7 Hph homophenylalanine; 8 Hse homoserine; 9 Hpla p-hydroxyphenyllactic acid; 10 HLE human leukocyte elastase.
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2. Results
2.1. LC-MS/MS Analysis of Cyanopeptolins
Fractionation of N. edaphicum CCNP1411 crude extract (Figure S1) resulted in isolation of thirteen
CPs. Structures were identified using a quadrupole/time of flight mass spectrometer and a triple
quadrupole/linear ion trap mass spectrometer (Table 2). Structural elucidation of the peptides was
based on fragmentation spectra with diagnostic ions, including immonium ions and a series of other
fragment ions associated with specific residues. Depending on the residue in position 2, two types of
spectra were obtained. Arg2-containing CPs (CPs-Arg2), gave pseudomolecular ions [M + H]+ at m/z
1049, 1021, 1019, 1007, 979, 993, 991, and 963. The Tyr2-containing peptides (CPs-Tyr2) were detected
as dehydrated protonated molecules [M + H − H2O]+ at m/z 1010, 996, 982, 968, and 952, and the
Tyr-immonium ion (m/z 136) was always present in their spectra. The putative planar structures of
CPs detected in N. edaphicum CCNP1411 and their fragmentation spectra are presented in Figures 1–4
and in supplementary information (Figures S2–S12). Amino acids at positions 1, 3, 4, 6, and 7 were
found to be conserved and occupied by Thr1, Ahp3, Phe4, Val6, and Asp7, respectively. The ion peak
corresponding to the longest sequence of residues common to all CP variants was observed in the
spectra at m/z 297 [Asp + Thr + Val + H − H2O]+ or/and at m/z 269 [Asp + Thr + Val + H − H2O
− CO]+. The presence of butanoic acid (BA), hexanoic acid (HA), or octanoic acid (OA) in the side
chain was mainly indicated by ion peaks formed by the cleavage of the corresponding fatty acid group
(FA) and the exocyclic aspartic acid (Figures 3 and 4; Figures S2–S12). As this cleavage produced a
stable cyclic part of the molecule, the ions [M + H − (H2O) − (FA + Asp)]+ usually belonged to the
most abundant ones. The residue in position 5 (i.e., N-MePhe, N-MeTyr or N-MeHty) was identified
based on immonium ion peaks at m/z 134, 150 or 164, respectively, and peaks at m/z 404, 420, and 434
corresponding to [Ahp + Phe + (MePhe/MeTyr/MeHty) + H − H2O]+. Ion peak at m/z 120, as well as
peaks at 243 [Ahp + Phe + H − H2O]+ and 215 [Ahp + Phe + H − H2O − CO]+ confirmed the presence
of Phe in position 4.
Mar. Drugs 2018, 16, x FOR PEER REVIEW  5 of 19 
 
2. Results 
2.1. LC-MS/MS Analysis of Cyanopeptolins 
Fractionation of N. edaphicum CCNP1411 crude extract (Figure S1) resulted in isolation of 
thirteen CPs. Structures were identified using a quadrupole/time of flight mass spectrometer and a 
triple quadrupole/linear ion trap mass spectrometer (Table 2). Structural elucidation of the peptides 
was based on fragmentation spectra with diagnostic ions, including immonium ions and a series of 
other fragment ions associated with specific residues. Depending on the residue in position 2, two 
types of spectra were obtained. Arg2-containing CPs (CPs-Arg2), gave pseudomolecular ions [M + H]+ 
at m/z 1049, 1021, 1019, 1007, 979, 993, 991, and 963. The Tyr2-containing peptides (CPs-Tyr2) were 
detected as dehydrated protonated molecules [M + H − H2O]+ at m/z 1010, 996, 982, 968, and 952, and 
the Tyr-immonium ion (m/z 136) was always present in their spectra. The putative planar structures 
of CPs detected in N. edaphicum CCNP1411 and their fragmentation spectra are presented in Figures 
1–4 and in supplementary information (Figures S2–S12). Amino acids at positions 1, 3, 4, 6, and 7 
were found to be conserved and occupied by Thr1, Ahp3, Phe4, Val6, and Asp7, respectively. The ion 
peak corresponding to the longest sequence of residues common to all CP variants was observed in 
the spectra at m/z 297 [Asp + Thr + Val + H − H2O]+ or/and at m/z 269 [Asp + Thr + Val + H − H2O − 
CO]+. The presence of butanoic acid (BA), hexanoic acid (HA), or octanoic acid (OA) in the side chain 
was mainly indicated by ion peaks formed by the cleavage of the corresponding fatty acid group (FA) 
and the exocyclic aspartic acid (Figures 3 and 4; Figures S2–S12). As this cleavage produced a stable 
cyclic part of the molecule, the ions [M + H − (H2O) − (FA + Asp)]+ usually belonged to the most 
abundant ones. The residue in position 5 (i.e., N-MePhe, N-MeTyr or N-MeHty) was identified based 
on immonium ion peaks at m/z 134, 150 or 164, respectively, and peaks at m/z 404, 420, and 434 
corresponding to [Ahp + Phe + (MePhe/MeTyr/MeHty) + H − H2O]+. Ion peak at m/z 120, as well as peaks 
at 243 [Ahp + Phe + H − H2O]+ and 215 [Ahp + Phe + H − H2O − CO]+ confirmed the presence of Phe in 
position 4. 
 
Figure 3. The product ion mass spectra of CP985 [Thr+Tyr+Ahp+Phe+MeTyr+Va]Asp+BA with 
precursor ion [M + H − H2O] at m/z 968. The spectra were recorded with application of a hybride 
quadrupole/time-of-flight mass spectrometer (QTOF) (A) and a hybride triple quadrupole/linear ion 
trap mass spectrometer (QTRAP) (B). The mass signals were assigned to the following fragments: 950 
[M + H − 2H2O]+, 869 [M + H − Val − H2O]+, 851 [M + H − Val − 2H2O]+, 773 [M + 2H − (BA+Asp) − CO]+, 
765 [M + 2H − (BA + Asp) − 2H2O]+, 692 [M + H − (Val + MeTyr) − H2O]+, 674 
[M+H−(Val+MeTyr)−2H2O]+, 646 [M + H − (Val + MeTyr) − 2H2O − CO]+, 432 [M + H − (Val + MeTyr + 
Phe + Ahp) − H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 404 [M + H − (Val + MeTyr + Phe + Ahp) − 
H2O − CO]+, 386 [BA + Asp + Thr + Val + H]+, 308 [Phe(−N) + MeTyr + H]+, 297 [Asp + Thr + Val + H − 
H2O − CO]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 150 MeTyr immonium 
ion, 136 Tyr immonium ion, 120 Phe immonium ion. 
Figure 3. The product ion mass spectra of CP985 [Thr+Tyr+Ahp+Phe+MeTyr+Va]Asp+BA with
precursor ion [M + H − H2O] at m/z 968. The spectra were recorded with application of a hybride
quadrupole/time-of-flight mass spectrometer (QTOF) (A) and a hybride triple quadrupole/linear ion
trap mass spectrometer (QTRAP) (B). The mass signals were assigned to the following fragments:
950 [M + H − 2H2O]+, 869 [M + H − Val − H2O]+, 851 [M + H − Val − 2H2O]+, 773 [M + 2H −
(BA+Asp) − CO]+, 765 [M + 2H − (BA + Asp) − 2H2O]+, 692 [M + H − (Val + MeTyr) − H2O]+, 674
[M+H−(Val+MeTyr)−2H2O]+, 646 [M + H − (Val + MeTyr) − 2H2O − CO]+, 432 [M + H − (Val +
MeTyr + Phe + Ahp) − H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 404 [M + H − (Val + MeTyr +
Phe + Ahp) − H2O − CO]+, 386 [BA + Asp + Thr + Val + H]+, 308 [Phe(−N) + MeTyr + H] , 297 [Asp
+ Thr + Val + H − H2O − CO]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+,
150 MeTyr immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion.
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Table 2. Cyanopeptolins identified in Nostoc edaphicum CCNP 1411. The activities of the peptides were assessed in serine proteases (trypsin, chymotrypsin, elastase,
and thrombin) and protein phosphatases 1 (PP 1) inhibition assays (- not active; */** small/medium activity; m/z of precursor ions: [M + H]+ for CPs-Arg2 and [M +
H − H2O]+ for CPs-Tyr2.
Cyanopeptolin CP m/z Structure
Enzyme Inhibition (IC50 [µM])
Chymotrypsin Trypsin Elastase Thrombin ProteinPhosphatase 1
CP 1048 1049 [Thr+Arg+Ahp+Phe+MeHty+Val]Asp+OA * ** - - -
CP 1020 1021 [Thr+Arg+Ahp+Phe+MeHty+Val Asp+HA 3.1 0.25 - - -
CP 1018 1019 [Thr+Arg+Ahp+Phe+MePhe+Val]Asp+ OA - 0.24 - - -
CP 1006 1007 [Thr+Arg+Ahp+Phe+MeTyr+Val]Asp+HA * ** - - -
CP 992 993 [Thr+Arg+Ahp+Phe+MeHty+Val]Asp+BA 3.5 0.24 - - -
CP 990 991 [Thr+Arg+Ahp+Phe+MePhe+Val]Asp+HA - ** - - -
CP 978 979 [Thr+Arg+Ahp+Phe+MeTyr+Val]Asp+BA 3.8 0.26 - - -
CP 962 963 [Thr+Arg+Ahp+Phe+MePhe+Val]Asp+BA - ** - - -
CP 1027 1010 [Thr+Tyr+Ahp+Phe+MeHty+Val]Asp+HA 0.26 - - - -
CP 1013 996 [Thr+Tyr+Ahp+Phe+MeTyr+Val]Asp+HA ** - - - -
CP 999 982 [Thr+Tyr+Ahp+Phe+MeHty+Val]Asp+BA ** - -. - -
CP 985 968 [Thr+Tyr+Ahp+Phe+MeTyr+Val]Asp+BA 0.26 - - - -
CP 969 952 [Thr+Tyr+Ahp+Phe+MePhe+Val]Asp+BA ** - - - -
Mar. Drugs 2018, 16, 220 7 of 19
Mar. Drugs 2018, 16, x FOR PEER REVIEW  7 of 19 
 
  
Figure 4. The product ion mass spectra of CP962 [Thr+Arg+Ahp+Phe+MePhe+Val]Asp+BA with 
precursor ion [M + H]+ at m/z 963. The spectra were recorded with application of a hybride 
quadrupole/time-of-flight mass spectrometer (QTOF) (A) and a hybride triple quadrupole/linear ion 
trap mass spectrometer (QTRAP) (B). The mass signals were assigned to the following fragments: 945 
[M + H − H2O]+, 917 [M + H − H2O − CO]+, 846 [M + H − Val − H2O]+, 828 [M + H − Val − 2H2O]+, 778 
[M + 2H − (BA + Asp)]+, 760 [M + 2H − (BA + Asp) − H2O]+, 742 [M + 2H − (BA + Asp) − 2H2O]+, 685 [M 
+ H − (Val + MePhe) − H2O]+, 425 [BA + Asp + Thr + Arg + H − H2O]+, 404 [Ahp + Phe + MePhe + H − 
H2O]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − 
CO]+, 134 MePhe immonium ion, 120 Phe immonium ion, 70-Arg. 
2.2. NMR Analysis 
In order to confirm the structures, two CPs (i.e., CP962 and CP985) were purified in sufficient 
quantities for NMR spectroscopy. For both compounds the 1H-NMR spectra displayed the typical 
pattern of a peptide (i.e., doublet amide protons (δH 6.95–8.51 ppm) and a single amide methyl group 
(δH 2.71 ppm for CP985 and 2.84 ppm for CP962). The COSY, TOCSY, and HMBC experiments 
allowed assignment of NMR spin systems to Asp, Thr, Tyr, Ahp (3-amino-6-hydroxypiperid-2-one), 
Phe, MeTyr (N-methyl tyrosine), Val, and butanoic acid (BA) in the case of cyanopeptolin CP985 
(Table 3, Figures S13–S18b). The presence of aromatic amino acid residues was recognized by the 
signals occurring in the aromatic region of the spectrum (δH 6.5–7.5 ppm). The AA’BB’ spin systems 
between two sets of tyrosine (Tyr-H2′/6′ and Tyr-H3′/5′, JH,H = 8.4 Hz) and N-methyl tyrosine aromatic 
protons (MeTyr-H2′/6′ and MeTyr-H3′/5′, JH,H = 8.4 Hz) indicated the presence of two para-di-
substituted phenyl rings. The 1H-13C long range correlation from MeTyr-NH-CH3 group (δH 2.71 
ppm) to the MeTyr-C2 atom (δC 61.3 ppm) revealed the presence of N-methyl tyrosine residue. 
Phenylalanine was found to be the third aromatic amino acid residue based on the COSY interaction 
between Phe-H2′/6′, Phe-H3′/5′, and Phe-H4′, and the HMBC correlation from two diastereotopic 
methylene protons Phe-3a (δH 2.88 ppm) and Phe-3b (δH 1.81 ppm) to the aromatic Phe-C2′/6′ carbons. 
The presence of Asp, Val, and Thr was confirmed by their characteristic spin systems in the COSY 
spectrum (Figure S17b). The macrocyclic ring closure between threonine and valine was verified by 
HMBC correlation between Thr-H3 (δH 5.36 ppm) and Val-C1 (δC 172.4 ppm) (Figure S15b). The 
presence of Ahp residue was detected by the characteristic signal of the OH proton (δH 5.99 ppm) and 
a broad singlet (δH 5.06 ppm) derived from H5 proton (Figure S13). The HMBC correlations from 
Ahp-C1 to Ahp-H5 and Ahp-H2 confirmed the cyclic nature of this residue.  
The COSY, TOCSY, and HMBC data allowed identification of amino acid residues in CP CP962 
as Asp, Thr, Arg, Ahp, Phe, MePhe (N-methyl phenylalanine), Val, and BA, analogously to CP985 
(Table 4, Figures S19–S24b). Two aromatic residues were found: phenylalanine and N-methyl 
phenylalanine. The occurrence of N-methyl group was established by the 1H-13C long range 
correlation from MePhe-NH-CH3 group (δH 2.84 ppm) to the MePhe-C2 atom. The typical 13C 
chemical shift of the guanidine quaternary carbon (δC 158.7 ppm) indicated the presence of Arg whose 
complete spin system was assigned based on TOCSY and COSY interactions (Figure S23b). The 
diagnostic regions of the TOCSY, ROESY and HMBC spectra of both cyanopeptolins analyzed are 
presented in corresponding figures in Supplementary 
Figure 4. The product ion mass spectra of CP962 [Thr+Arg+Ahp+Phe+MePhe+ al] sp+ it
precursor ion [ + H]+ at m/z 963. e s ectra ere rec r e it a licati f a hybride
qua r ole ti e-of-flight ass spectrometer (QTOF) (A) and a hybride triple quadrupole/linear
ion trap mass spectrometer (QTRAP) (B). The mass signals were assigned to the following fragments:
945 [M + − H2O]+, 917 [M + H − H2O − CO]+, 846 [M + H − Val − H2O]+, 828 [M + H − Val −
2H2O]+, 778 [M + 2H − (BA + Asp)]+, 760 [M + 2H (BA + Asp) − H2O]+, 742 [M + 2H − (BA + Asp)
− 2H2O]+, 685 [M + H − (Val + MePhe) − H2O]+, 425 [BA + Asp + Thr + Arg + H − H2O]+, 404 [Ahp
+ Phe MePhe + H − H2O]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215
[Ahp + Phe + H − H2O − CO]+, 134 MePhe immonium ion, 120 Phe immonium ion, 70-Arg.
2.2. NMR Analysis
In order to confirm the structures, two CPs (i.e., CP962 and CP985) were purified in sufficient
quantities for NMR spectroscopy. For both compounds the 1H-NMR spectra displayed the typical
pattern of a peptide (i.e., doublet amide protons (δH 6.95–8.51 ppm) and a single amide methyl group
(δH 2.71 ppm for CP985 and 2.84 ppm for CP962). The COSY, TOCSY, and HMBC experiments allowed
assignment of NMR spin systems to Asp, Thr, Tyr, Ahp (3-amino-6-hydroxypiperid-2-one), Phe, MeTyr
(N-methyl tyrosine), Val, and butanoic acid (BA) in the case of cyanopeptolin CP985 (Table 3, Figures
S13–S18b). The presence of aromatic amino acid residues was recognized by the signals occurring
in the aromatic region of the spectrum (δH 6.5–7.5 ppm). The AA’BB’ spin systems between two
sets of tyrosine (Tyr-H2′/6′ and Tyr-H3′/5′, JH,H = 8.4 Hz) and N-methyl tyrosine aromatic protons
(MeTyr-H2′/6′ and MeTyr-H3′/5′, JH,H = 8.4 Hz) indicated the presence of two para-di-substituted
phenyl rings. The 1H-13C long range correlation from MeTyr-NH-CH3 group (δH 2.71 ppm) to the
MeTyr-C2 atom (δC 61.3 ppm) revealed the presence of N-methyl tyrosine residue. Phenylalanine was
found to be the third aromatic amino acid residue based on the COSY interaction between Phe-H2′/6′,
Phe-H3′/5′, and Phe-H4′, and the HMBC correlation from two diastereotopic methylene protons
Phe-3a (δH 2.88 ppm) and Phe-3b (δH 1.81 ppm) to the aromatic Phe-C2′/6′ carbons. The presence
of Asp, Val, and Thr was confirmed by their characteristic spin systems in the COSY spectrum
(Figure S17b). The macrocyclic ring closure between threonine and valine was verified by HMBC
correlation between Thr-H3 (δH 5.36 ppm) and Val-C1 (δC 172.4 ppm) (Figure S15b). The presence of
Ahp residue was detected by the characteristic signal of the OH proton (δH 5.99 ppm) and a broad
singlet (δH 5.06 ppm) derived from H5 proton (Figure S13). The HMBC correlations from Ahp-C1 to
Ahp-H5 and Ahp-H2 confirmed the cyclic nature of this residue.
The COSY, TOCSY, and HMBC data allowed identification of amino acid residues in CP CP962 as
Asp, Thr, Arg, Ahp, Phe, MePhe (N-methyl phenylalanine), Val, and BA, analogously to CP985
(Table 4, Figures S19–S24b). Two aromatic residues were found: phenylalanine and N-methyl
phenylalanine. The occurrence of N-methyl group was established by the 1H-13C long range correlation
from MePhe-NH-CH3 group (δH 2.84 ppm) to the MePhe-C2 atom. The typical 13C chemical shift
of the guanidine quaternary carbon (δC 158.7 ppm) indicated the presence of Arg whose complete
spin system was assigned based on TOCSY and COSY interactions (Figure S23b). The diagnostic
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regions of the TOCSY, ROESY and HMBC spectra of both cyanopeptolins analyzed are presented in
corresponding figures in Supplementary.
Table 3. NMR Spectroscopic data (700 MHz, DMSO-d6) for cyanopeptolin CP985
[Thr+Tyr+Ahp+Phe+MeTyr+Val]Asp+BA.
Unit Position δC δH (J in Hz) ROESY HMBC a
BA
1
2
3
4
172.9, C
37.7, CH2
19.2, CH2
14.2, CH3
2.11, m
1.56, m
0.89, t (7.2, 7.2)
Asp-NH
BA-1, BA-3, BA-4
BA-1, BA-2, BA-4
BA-2
Asp
1
2
3a
3b
4
NH
171.7, C
49.9, CH
36.1, CH2
172.4, C
4.58, dd (8.0, 5.0)
2.65, m
2.46, m
8.26, m
Thr-NH Asp-4
Thr1
1
2
3
4
NH
168.9, C
54.7, CH
72.6, CH
18.0, CH3
4.52, d (10.0)
5.36, q (6.8, 6.9, 6.8)
1.16, d (7.2)
7.52, d (9.3)
Tyr-NH
Tyr-NH
Asp-2
Thr-1, Asp-1
Val-1
Thr-2, Thr-3
Tyr2
1
2
3a
3b
1’
2′/6′
3′/5′
4′
NH
169.9, C
54.2, CH
35.5, CH2
128.5, C
130.1, CH
115.5, CH
156.1, C
4.31, m
3.11, m
2.55, m
6.89, d (8.4)
6.58, d (8.4)
8.46, d (8.8)
Ahp-NH
Thr-2, Thr-3
Tyr-2, Tyr-1′
Tyr-1′
Tyr-4′
Thr-1
Ahp3
1
2
3
4
5
NH
OH
169.0, C
49.4, CH
22.0, CH2
21.9, CH2
74.1, CH
3.62, m
2.41, m
1.64, m
5.06, brs
7.06, d (8.8)
5.99, d (3.1)
Ahp-NH
Phe-3a,
Phe-3b
Tyr-2,
Ahp-3
Ahp-1, Ahp-3
Ahp-2
Ahp-1
Tyr-1
Phe4
1
2
3a
3b
1′
2′/6′
3′/5′
4′
170.8, C
50.7, CH
35.8, CH2
137.2, C
129.9, CH
128.2, CH
126.7, CH
4.76, dd (7.1, 4.6)
2.88, t (12.9, 12.9)
1.81, dd (10.4, 3.9)
6.84, d (7.0)
7.19, t (7.3, 7.3)
7.14, d (7.0)
Ahp-5
Phe-2, Phe-1′, Phe-2′/6′
Phe-3a, Phe-3b, Phe-4′
Phe-1′
Phe C2′/6′
MeTyr5
1
2
3
1′
2′/6′
3′/5′
4′
NCH3
OH
169.4, C
61.3, CH
33.3, CH2
128.2, C
130.9, CH
115.5, CH
156.7, C
33.3, CH3
4.89, dd (8.9, 2.5)
3.10, m
7.00, d (8.4)
6.78, d (8.4)
2.71, s
9.33, s
Val-NH
MeTyr-1′
MeTyr-1′, MeTyr-3′/5′
MeTyr-2′/6′, MeTyr-4′
MeTyr-2, Phe-1
MeTyr-3′/5′, MeTyr-4′
Val6
1
2
3
4
5
NH
172.4, C
56.3, CH
31.4, CH
19.7, CH3
17.7, CH3
4.63, dd (4.9, 4.6)
2.02, m
0.84, d (6.6)
0.71, d (6.6)
7.39, d (9.7)
MeTyr-2
Val-2, Val-3, Val-5
Val-2, Val-3, Val-4
MeTyr-1
a HMBC correlations are given from proton(s) stated to the indicated carbon atom.
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Table 4. NMR Spectroscopic data (700 MHz, DMSO-d6) for cyanopeptolin CPL962
[Thr+Arg+Ahp+Phe+MePhe+Val]Asp+BA.
Unit Position δC δH (J in Hz) ROESY HMBC a
BA
1
2
3
4
172.2, C
37.4, CH2
19.3, CH2
14.1, CH3
2.08, m
1.52, m
0.87, t (7.4, 7.4)
Asp-NH
BA-1, BA-3, BA-4
BA-1, BA-2, BA-4
BA-2
Asp
1
2
3a
3b
4
NH
173.7, C
50.8, CH
40.1, CH2
175.3, C
4.54, m
2.51, m
2.12, m
8.00, d (8.0)
Thr-NH Asp-2, Asp-4BA-1
Thr1
1
2
3
4
NH
169.9, C
55.0, CH
72.3, CH
17.9, CH3
4.58, d (9.0)
5.30, q (6.8, 6.5, 6.8)
1.15, d (6.5)
7.23, d (7.6)
Arg-NH
Arg-NH
Asp-2
Thr-1
Thr-4, Val-1
Thr-2, Thr-3
Arg2
1
2
3
4
5
6
NH
170.4, C
49.0, CH
26.4, CH2
24.5, CH2
39.8, CH2
158.7, C
4.15, m
1.88, m
1.46, m
2.95, m
8.5, d (8.7)
Ahp-NH
Thr-2, Thr-3 Thr-1
Ahp3
1
2
3
4
5
NH
OH
169.6, C
48.6, CH
21.7, CH2
22.0, CH2
74.2, CH
3.65, m
2.43, m
1.68, m
5.03, brs
6.95, d (9.7)
6.01, d (2.6)
Phe-3a, Phe-3b
Arg-2, Ahp-3
Ahp-1, Ahp-3
Ahp-1
Arg-1
Phe4
1
2
3a
3b
1′
2′/6′
3′/5′
4′
170.0, C
50.6, CH
35.6, CH2
137.1, C
129.8, CH
128.2, CH
126.7, CH
4.74, dd (7.2, 3.5)
2.86, m
1.69, m
6.78, d (7.1)
7.17, t (7.1, 7.1)
7.13, d (7.8)
Ahp-5
Phe-1, Phe-3a, Phe-3b
Phe-1′
Phe-3a, Phe-3b, Phe-4′
Phe-1′
Phe-3′/5′
MePhe5
1
2
3
1′
2′/6′
3′/5′
4′
NCH3
169.4, C
60.9, CH
34.4, CH2
138.4, C
130.0, CH
129.1, CH
127.2, CH
35.6, CH3
5.02, m
3.23, m
7.24, d (7.6)
7.41, t (7.7, 7.7)
7.32, d (7.5)
2.84, s
Val-NH
MePhe-1′
MePhe-1′
MePhe-4′
MePhe-3′/5′
MePhe-2
Val6
1
2
3
4
5
NH
172.6, C
56.4, CH
31.6, CH
19.7, CH3
17.8, CH3
4.71, dd (5.2, 4.2)
2.05, m
0.88, d (6.9)
0.76, d (6.9)
7.41, d (7.7)
MePhe-2
Val-3
Val-2, Val-3, Val-5
Val-2, Val-3, Val-4
MePhe-1
a HMBC correlations are given from proton(s) stated to the indicated carbon atom.
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2.3. Bioassays
Preparative chromatography resulted in separation of several fractions containing thirteen pure
cyanopeptolin variants (Table 2). These peptides were evaluated for inhibition against four serine
proteases and protein phosphatase 1. In addition, their effect on MCF-7 breast cancer cells was
tested. However, only six CPs were isolated from N. edaphicum CCNP1411 in sufficient amounts to
obtain quantitative results of the assays. None of the peptides were active against thrombin, elastase,
and protein phosphatase 1, even at the highest concentration used in the study (45.4 µg/mL). However,
all CPs with Arg in position 2 significantly reduced the activity of trypsin. The IC50 values of trypsin
inhibitors were comparable and in the range of 0.24–0.26 µM. The CPs-Arg2 with N-MeTyr or N-MeHty
in position 5 were also active against chymotrypsin, but the IC50 values were lower (IC50 = 3.1–3.8 µM).
Chymotrypsin inhibition activity of CPs-Arg2 was not observed when position 5 was occupied by
MePhe. All CPs-Tyr2 reduced activity of chymotrypsin and were inactive against other enzymes.
For CP1027 and CP985, the IC50 was 0.26 µM. Following enzyme inhibition assays, all samples with
Arg2-containing CP962 and Tyr2-containing CP985 (at 4.54 µg/mL) were analyzed by LC-MS/MS.
The recovery was based on extracted mass chromatogram of parent ions. The enzymes did not cause
any significant loss of the peptides; their contents were in the range from 94.6% to 97.7% of that in
samples without the enzyme.
Due to limited amounts of pure peptides isolated from N. edaphicum CCNP1411, only
Arg2-containing CP962 and Tyr2-containing CP985 were used in MTT (3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyltetrazolium bromide) assay. After 24-h exposure, no cytotoxic effects on the MCF-7 cells
were observed (Figure 5).
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3. Discussion
Cyanobacteria from the Nostoc genus, especially the symbiotic strains and those living in waters
from tropical regions, are important producers of bioactive compounds with potential biotechnological
or pharmaceutical application [37,40–43]. One of the most prominent examples are cryptophycins,
cyclic depsipeptides isolated from Nostoc sp. ATCC 53789 and GSV 224. They are promising candidates
for anti-cancer drug development [44,45]. Another important Nostoc metabolite is cyanovirin-N,
a small cyanobacterial lectin which blocks the entry of the enveloped viruses such as HIV, influenza,
and Ebola [46].
In this study, the structures of CPs produced by N. edaphicum CCNP1411 from the Baltic
Sea were elucidated based on the fragmentation spectra of their pseudomolecular ions (CPs-Arg2)
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(Figure 4; Figures S2–S8) or the dehydrated forms of the ions (CPs-Tyr2) (Figure 3; Figures S9–S12).
The occurrence of the dehydrated pseudomolecular ion as a precursor ion in mass fragmentation
spectra of Tyr2-(and Ile2)-containing aeruginopeptins has been previously reported [20,47]. It was
suggested that the cleavage of an ester bond at Thr1 and subsequent dehydration resulted in the
generation of linear peptides. For the two CPs, Arg2-containing CP962 and Tyr2-containing CP985,
the composition and sequences of amino acids were confirmed by NMR spectroscopy. The results
of the analyses were consistent with structure elucidation performed by tandem mass spectrometry.
The core structures of these peptides were more similar to those identified in Microcystis [13,14,28,32],
compared to those reported from other Nostoc isolates (Table 1). For example, instead of Arg2 or Tyr2
present in position 2 of the CPs identified in this work, nostopeptin and insulapeptolides from N.
minutum and N. insulare possess Leu2 or Hph2 (homophenylalanine) [35,38]. Of the CPs identified in
this study, only CP1006A (m/z 1007) was previously reported. This peptide, along with its chlorinated
derivative (CP1040A) were found in Microcystis bloom and culture samples [14,48].
The structural diversity of CPs, specifically the residue in position 2, was found to have significant
effect on activity of the peptides against serine proteases: trypsin and chymotrypsin [28,29,32].
The CP-type peptides with potent inhibitory activity against trypsin were characterized by the presence
of basic amino acid (Arg or Lys), whereas in peptides active against chymotrypsin, position 2 was
occupied by hydrophobic residues (Tyr, Phe, Hty or Leu). The same structure-activity relationship was
observed in this study. Eight CPs-Arg2 inhibited the activity of trypsin with IC50 values of 0.24–0.26 µM,
and five CPs-Tyr2 inhibited chymotrypsin with similar potency. In addition, the inhibitory activity of
CPs produced by CCNP1411 seemed to be affected by the residue in position 5. Only those CPs-Arg2
which had N-MeTyr5 or N-MeHty5 in this position were active against chymotrypsin. However,
to unequivocally prove the significance of this structure-activity relationship, more CPs should be
tested. The fact that some CPs-Arg2, apart from strong inhibition of trypsin, are also active against
chymotrypsin was previously documented by other authors [12,29,49]. The trypsin inhibition activity
of CP-type peptides was suggested to be enhanced by the presence of isoleucine in position 6, instead
of valine. Other modifications in the structure of Ahp-containing cyclic depsipeptides, such as the
presence of chloride or sulfide groups, may also have an effect on enzyme inhibition activity [12].
Cyanobacteria produce many other Ahp-containing cyclic depsipeptides with inhibitory activity
against proteases [28,29]. The majority of the peptides were active at micromolar concentrations,
but some had even lower IC50 values. Symplocamide A, with citrulline in position 2, showed potent
activity against chymotrypsin with IC50 of 0.38 µM, and was 200-times less active against trypsin
(IC50 80.2 µM) [29]. Symplocamide A also had cytotoxic activity to NCI H460 lung cancer cells and
neuro-2A neuroblastoma cells [29]. Chymotrypsin was most potently inhibited by the glyceric acid
3′-O-phosphate-containing micropeptin T20 from M. aeruginosa, characterized by the presence of the
Thr-Phe-Ahp sequence (IC50 2.5 nM) [50]. Picomolar inhibition of trypsin was documented for CP
1020, which was also active against chymotrypsin, plasmin, human kallikrein, and factor XIa [32].
The structure of CP1020 differs from CP978 isolated in our study only in the presence of Glu in a side
chain, instead of Asp. In enzymatic assays, CP978 and other CPs isolated from N. edaphicum CCNP1411
were less active than CP1020, but still belong to the most potent protease inhibitors among this class of
compounds [12,28,29,32]. Ahp-containing depsipeptides were suggested to block the active center of
trypsin or/and chymotrypsin, so the enzymes cannot cleave the peptide bonds at the carboxyl side of
Arg or Tyr, respectively [25,28]. In this study, the Tyr2-containing CP985 and Arg2-containing CP962
exposed to proteases inhibited the activity of chymotrypsin or/and trypsin, but their concentrations
remained almost unchanged. These results are in line with the hypothesis by Yamaki et al. [28] and
confirm the blockage of the active centers of the enzymes by the peptides.
Trypsin and chymotrypsin, the two enzymes inhibited by CPs from CCNP1411, are essential
for food digestion. Their deregulation can also lead to a number of human diseases such as cancer,
cardiovascular and inflammatory diseases. The molecules that modify activity of these proteases,
and especially those that act selectively, are widely explored as agents of significant biotechnological
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and pharmaceutical potential [51]. As the new CP variants identified in N. edaphicum CCNP1411
inhibited the activity of trypsin or chymotrypsin at low concentrations and were inactive against the
other tested enzymes and MCF-7 breast cancer cells, their possible use as therapeutic agents should be
further explored.
Besides its therapeutic potential, this class of protease inhibitors was proven to be an important
group of defense agents protecting cyanobacteria from grazers. Oscillapeptin J, CP SS and CP 1020
induced acute effects in small crustaceans [18,32,33]. However, CP SS was not toxic to the isolated rat
hepatocytes [18], and oscillapeptin J did not induce any harmful effects in mice when administered
intraperitoneally at concentrations up to 1000 µg/kg b.w. [52]. In the case of CP1020, induction of
anti-inflammatory effects in human hepatoma cell line Huh7 was observed [53]. In addition, exposure
of zebrafish eleuthero-embryos to CP1020 led to transcriptional alterations of genes involved in many
important processes, including DNA damage recognition and repair, and circadian rhythm [54].
These findings, along with the acute toxicity of CP-type compounds observed in crustaceans suggest
that their activity is not only related to the inhibition of digestive enzymes.
4. Materials and Methods
4.1. Culture Conditions
Nostoc cf. edaphicum CCNP 1411 (GenBank accession number KJ161445) was isolated in 2010
from the Gulf of Gdan´sk, southern Baltic Sea, and established as monospecies culture by Dr. Justyna
Kobos. Purification of the strain was carried out by multiple transfer to a liquid or/and solid (1%
bacterial agar) Z8S medium [55]. To obtain a higher biomass of the cyanobacterium, the culture was
grown in 5-L bottles at 22 ◦C ± 1 ◦C, at continuous light of 10–30 µE/m2/s. The collected biomass was
lyophilized and kept at −20 ◦C until used.
4.2. Extraction and Isolation
Freeze-dried biomass of N. edaphicum (36 g) was extracted twice with 75% methanol (MeOH)
(1 L) by vortexing for 30 min. Following centrifugation at 4,000 g, the extracts were pooled
and diluted in water purified using ELGA PURELAB® flex (Veoilia, London, UK) to adjust the
concentration of MeOH to <10%. Then, the sample was loaded onto the preconditioned 120-g SNAP
KP-C18-HS cartridge (Biotage Uppsala, Sweden). Sample components were eluted using an Isolera
flash chromatography system (Biotage Uppsala, Sweden), with a step gradient (10–100% MeOH in
water) with 3 column volumes of eluent at each step. Absorbance was monitored at 210 nm and
280 nm. The flow rate was 40 mL/min and 60-mL fractions were collected. Fraction composition
was analyzed by UPLC-MS/MS. Fractions containing the same peptides were pooled, diluted with
water to <10% MeOH, and concentrated on YMC C18 cartridges (20 mm ID × 2 cm; YMC, Gmbh,
Dinslaken, Germany).
Six pooled fractions were further purified using preparative HPLC (Biotage Parallex Flex, Cardiff,
UK) and Flex V3 software for instrument control and data acquisition. The separation was performed
on XBridge Prep C18 column (5 µm CBD, 19 mm ID × 250 mm long; Waters, Elstree, UK) using a
30-min linear gradient from 15% to 80% acetonitrile in MilliQ water with 0.1% formic acid. Absorbance
was monitored at 210 nm and 280 nm. The flow rate was 20 mL/min and 4-mL fractions were collected.
4.3. LC-MS/MS Analyses
At each step of the extraction and isolation procedure, the content of the collected fractions
was determined by UPLC-MS/MS. The system comprised a Waters Acquity Ultra performance LC
coupled to a photodiode array detector (PDA) and a Xevo quadrupole time of flight mass detector
(Waters, Elstree, UK). Samples were separated on an ethylene-bridged hybride BEH C18 column
(2.1 mm ID × 100 mm; 1.7 µm, Waters) maintained at 40 ◦C. The mobile phase was Milli-Q water
and acetonitrile (solvent B), both containing 0.1% formic acid. Separation was performed using
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gradient elution (0.3 mL/min) from 20% to 70% B over 10 min, followed by a 100% B wash step and
re-equilibration. Data was acquired in positive ion electrospray scanning from m/z 50 to 2000 with a
scan time of 2 s and inter-scan delay of 0.1 s. The capillary and cone voltages were set at 0.7 kV and
25 V, respectively. The desolvation gas was maintained at 400 L/h at a temperature of 300 ◦C. The cone
gas was set at 50 L/h with a source temperature of 80 ◦C. Instrument control, data acquisition and
processing were achieved using MassLynx v4.1 (Waters, Milford, MA, USA).
Structures of cyanopeptolins were additionally characterized using Agilent 1200 HPLC (Agilent
Technologies, Waldbronn, Germany) coupled to a hybrid triple quadrupole/linear ion trap mass
spectrometer QTRAP5500 (Applied Biosystems MDS Sciex, Concord, ON, Canada). Peptides were
separated on Zorbax Eclipse XDB-C18 column (4.6 mm ID × 150 mm, 5 µm; Agilent Technologies,
Santa Clara, CA, USA) column. A gradient elution (0.6 mL/min) was applied with mobile phase
composed of 5% acetonitrile in MilliQ water and acetonitrile (solvent B), both containing 0.1% formic
acid. The gradient started at 15% B and went to 50% B within 5 min. The content of phase B was
then increased to 100% within the next 3 min and kept at that level for 10 min before returning to
the starting conditions. The QTRAP MS/MS system was operated in the positive mode, with turbo
ion source voltage set at 5.5 kV and temperature at 550 ◦C. For ions within the m/z range 500–1250
and signal intensity above the threshold of 500,000 cps, fragmentation spectra were acquired within a
range 50–1000 Da, at collision energy of 60 V and declustering potential set at 80 eV. Data acquisition
and processing were accomplished with the Analyst® Sofware (version 1.5.1, Applied Biosystems,
Concord, ON, Canada).
4.4. NMR Analyses
1D 1H-NMR and 2D homo- and heteronuclear 2D NMR (COSY, TOCSY, ROESY, HSQC,
and HMBC) were acquired on a Bruker Avance III spectrometers, 500 MHz and 700 MHz. Spectra
were recorded in DMSO-d6. NMR data were processed and analyzed by TopSpin (Bruker, Billerica,
MA, USA) and SPARKY software (3.114, Goddard and Kneller, freeware https://www.cgl.ucsf.edu/
home/sparky).
4.5. Enzyme Inhibition Assay
The chymotrypsin and trypsin inhibition assays were performed following the procedures of
Ploutno and Carmeli [41]. The α-chymotrypsin from bovine pancreas (C4129), trypsin from porcine
pancreas (T0303), aprotinin (1.5–200 µg/mL) as enzyme inhibitor, N-Suc-Gly-Gly-p-nitroanilide
and N-α-benzoyl-DL-arginine-p-nitroanilide hydrochloride (BAPNA) as chymotrypsin and trypsin
substrates, respectively were used. Enzymes (0.1 mg/mL) and substrate (2 mM) were dissolved in
the same buffer (50 mM Tris-HCl, 100 mM NaCl, 1 mM CaCl2, pH 7.5). The thrombin inhibition
assay was performed according to Ocampo and Bennet [56]. Thrombin (T4648) was dissolved in
buffer (0.5 mg/mL; 0.2 M Tris-HCl; pH 8.0); substrate (N-p-tosyl-Gly-L-Pro-L-Lys-p-nitroanilide acetate
salt, 0.5 mg/mL) and inhibitor (4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF;
60–2400 µg/mL)) were dissolved in MilliQ water. The elastase inhibition assay was performed
according to Kwan et al. [57]. The enzyme (75 µg/mL; E0258) from porcine pancreas, substrate (2
mM; N-Suc-Ala-Ala-Ala-p-nitroanilide) and inhibitor (elastatinal; 5–125 µg/mL) were dissolved in
buffer (0.2 M Tris-HCl; pH 8.0). All enzymes, substrates and inhibitors used for proteases inhibition
assays were from Sigma-Aldrich (St. Louis, MO, USA). Protein phosphatase 1 inhibition assay was
performed according to the procedure described by Rapala et al. [58]. PP1 was from England Biolabs,
Hitchin, UK (754S) and the substrate, p-nitrophenyl phosphate disodium salt hexahydrate (p-NPP),
was from Sigma-Aldrich (Irvine, UK). Microcystin MC-LR (0.125–4.0 ng/mL) from Enzo Life Sciences,
Lausen, Switzerland was used as inhibitor. The enzyme was dissolved in buffer solution A (50
mM Tris at pH 7.4, 1 mg/mL bovine serum albumin (BSA; Sigma -Aldrich, St. Louis, MO, USA),
1 mM MnCl2, 2 mM dithiotreitol (DTT; Sigma-Aldrich, St. Louis, MO, USA)). p-NPP (5.5 mg/mL)
was dissolved in buffer solution B (50 mM Tris, pH 8.1, 0.5 mg/mL BSA, 20 mM MgCl2 × 6H2O,
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200 mM MnCl2 × 4H2O). All enzyme inhibition assays were performed in a 96 multi-well plate at
37 ◦C, in triplicate. The absorbance of the reaction mixtures was measured at 405 nm using a microplate
reader (Molecular Devices, Sunnyvale, CA, USA). After trypsin and chymotrypsin inhibition assays,
the samples with and without the enzymes and containing the highest concentration of CP962 and
CP985 (45.4 µg/mL) were analyzed by LC-MS/MS. The content of the peptides was determined based
of the peak area of the extracted ions.
4.6. Cytotoxicity Assay
For the test, two CPs were selected: Arg2-containing CP962 and Tyr2-containing CP985. MCF-7
breast cancer cells were seeded at 7.5 × 103 cells/100 µL in a 96-well plates and incubated at 37 ◦C, 5%
CO2 for 24 h. The cells were then treated for a further 24 h with CP962 and CP985 (0 to 500 µg/mL).
After 24 h, sterile-filtered 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (MTT;
1 mg/mL) was added to each well. After 4 h incubation at 37 ◦C in the dark, the MTT solution was
removed and formazan crystals solubilized in DMSO. The plates were shaken for 20 min, in the dark,
at room temperature and absorbance was measured at 560 nm (Synergy/HT, BIOTEK, Wnooski, VT,
USA). For each CP, three independent experiments were carried out and each treatment consisted of
six replicates per plate. Bar charts were used to represent the viability of MCF-7 cells treated with
CP962 and CP985, compared to the control (i.e., untreated cells) that represented 100% cell viability.
5. Conclusions
Nostoc edaphicum CCNP1411 isolated from the Gulf of Gdan´sk (southern Baltic) produces at least
thirteen CPs, including twelve variants reported here for the first time. The structures of the peptides
are different from other Ahp-containing cyclic depsipeptides previously found in Nostoc. The activity
of the peptides was mainly determined by the presence of Arg2 or Tyr2 in Ahp-adjacent position.
The fact that trypsin and chymotrypsin did not degrade the tested CPs constitutes an additional
evidence for enzyme inactivation by the peptides. Neither of the CP inhibited thrombin, elastase,
and protein phosphatase 1; CP962 and CP985 also showed no cytotoxic effects on MCF-7 breast cancer
cells. The CPs produced by N. edaphicum CCNP1411, as peptidic structures with selective and potent
proteases inhibiting activity, are potential lead compounds in drug discovery process.
Supplementary Materials: The following are available online at http://www.mdpi.com/1660-3397/16/7/220/s1.
Figure S1: LC-MS/MS chromatogram of cyjanopeptolins (CPs) in crude extract from Nostoc edaphicum CCNP1411
(A) and chromatograms of isolated peptides: CP962 (B) and CP985 (C); Figure S2: Chemical structure (A) and
product ion mass spectra of cyanopeptolin CP1049 [Thr+Arg+Ahp+Phe+MeHty+Val]Asp+OA with precursor
ion [M + H]+ at m/z 1049. The spectra were recorded with application of a hybride quadrupole/time-of-flight
mass spectrometer (QTOF) (B) and a hybride triple quadrupole/linear ion trap mass spectrometer (QTRAP)
(C). The mass signals were assigned to the following fragments: 1031 [M + H − H2O]+, 1003 [M + H − H2O
− CO]+, 932 [M + H − Val − H2O]+, 914 [M + H − Val − 2H2O]+, 808 [M + 2H − (Asp + OA)]+, 790 [M + 2H
− (Asp + OA) − H2O]+, 772 [M + 2H − (Asp + OA) − 2H2O]+, 741 [M + H − (Val + MeHty) − H2O]+, 673
[M + 2H − Val − (Asp + OA) − 2H2O]+, 481 [OA+Asp + Thr + Arg + H − H2O]+, 434 [Ahp + Phe + MeHty
+ H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+, 322 [Phe(−N) + MeHty + H]+, 297 [Asp + Thr + Val + H
− H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 164 MeHty immonium ion,
120 Phe immonium ion, 70-Arg; Figure S3: Chemical structure (A) and product ion mass spectra of cyanopeptolin
CP1020 [Thr+Arg+Ahp+Phe+MeHty+Val]Asp+HA with precursor ion [M + H]+ at m/z 1021. The spectra were
recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to
the following fragments: 1003 [M + H − H2O]+, 975 [M + H − H2O − CO]+, 886 [M + H − Val − 2H2O]+, 808
[M + 2H − (Asp + HA)]+, 790 [M + 2H − (Asp + HA) − H2O]+, 772 [M + 2H − (Asp + OA) − 2H2O]+, 713 [M +
H − (Val + MeHty) − H2O]+, 691 [M + 2H − Val − (Asp + HA) − H2O]+, 673 [M + 2H − Val − (Asp + HA) −
2H2O]+, 453 [HA + Asp + Thr + Arg + H − H2O]+, 434 [Ahp + Phe + MeHty + − H2O]+, 338 [Arg + Thr + Val + H
− H2O]+, 322 [Phe(-N) + MeHty + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215
[Ahp + Phe + H − H2O − CO]+, 164 MeHty immonium ion, 120 Phe immonium ion, 70-Arg; Figure S4: Chemical
structure (A) and product ion mass spectra of cyanopeptolin CP1018 [Thr+Arg+Ahp+Phe+MePhe+Val]Asp+OA
with precursor ion [M+H]+ at m/z 1019. The spectra were recorded with application of QTOF (B) and QTRAP (C)
mass spectrometers. The mass signals were assigned to the following fragments: 1001 [M + H − H2O]+, 983 [M +
H − 2H2O]+, 973 [M + H − H2O − CO]+, 902 [M + H − Val − H2O]+, 884 [M + H − Val − 2H2O]+, 778 [M + 2H
− (Asp + OA)]+, 760 [M + 2H − (Asp + OA) − H2O]+, 742 [M + 2H − (Asp + OA) − 2H2O]+, 661 [M + 2H − Val
− (Asp+OA) − H2O]+, 643 [M + 2H − Val − (Asp + OA) − 2H2O]+, 481 [OA + Asp + Thr + Arg + H − H2O]+,
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404 [Ahp + Phe + MePhe + H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+, 308 [Phe(-N) + MeTyr + H]+, 297
[Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 134 MePhe
immonium ion, 120 Phe immonium ion, 70-Arg; Figure S5: Chemical structure (A) and product ion mass spectra
of cyanopeptolin CP1006 [Thr+Arg+Ahp+Phe+MeTyr+Val]Asp+HA with precursor ion [M + H]+ at m/z 1007.
The spectra were recorded with application of QTOF (B) and QTRAP (A) mass spectrometers. The mass signals
were assigned to the following fragments: 989 [M + H − H2O]+, 961 [M + H − H2O − CO]+, 872 [M + H − Val −
2H2O]+, 794 [M + 2H − (Asp + HA)]+, 776 [M + 2H − (Asp + HA) − H2O]+, 766 [ M + 2H − (Asp + HA) − CO]+,
758 [M + 2H − (Asp + HA) − 2H2O]+, 713 [M + H − (Val + MeHTyr) − H2O]+, 659 [M + 2H − Val − (Asp + HA)
− 2H2O]+, 453 [HA + Asp + Thr + Arg + H − H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 338 [Arg + Thr + Val
+ H − H2O]+, 308 [Phe(−N) + MeTyr + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215
[Ahp + Phe + H − H2O − CO]+, 150 MeTyr immonium ion, 120 Phe immonium ion, 70-Arg; Figure S6: Chemical
structure (A) and product ion mass spectra of cyanopeptolin CP992 [Thr+Arg+Ahp+Phe+MeHty+Val]Asp+BA
with precursor ion [M + H]+ at m/z 993. The spectra were recorded with application of QTOF (B) and QTRAP
(C) mass spectrometers. The mass signals were assigned to the following fragments: 975 [M + H − H2O]+, 947
[M + H − H2O − CO]+, 858 [M + H − Val −-2H2O]+, 808 [M + 2H − (Asp + BA)]+, 790 [M + 2H − (Asp +
BA) − H2O]+, 772 [M + 2H − (Asp + BA) − 2H2O]+, 673 [M + 2H − Val − (Asp + BA) − 2H2O]+, 434 [Ahp
+ Phe + MeHty + H − H2O]+, 425 [BA + Asp + Thr + Arg + H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+,
322 [Phe(−N) + MeHty + H]+, 243 [Ahp + Ph + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 164 MeHty
immonium ion, 120 Phe immonium ion, 70-Arg; Figure S7: Chemical structure (A) and product ion mass spectra
of cyanopeptolin CP990 [Thr+Arg+Ahp+Phe +MePhe+Val]Asp+HA with precursor ion [M + H]+ at m/z 991.
The spectra were recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals
were assigned to the following fragments: 973 [M + H − H2O]+, 945 [M + H − H2O − CO]+, 856 [M + H − Val
− 2H2O]+, 778 [M + 2H − (Asp + HA)]+, 760 [M + 2H − (Asp + HA) − H2O]+, 750 [M + 2H − (Asp + HA) −
CO]+, 742 [M + 2H-(Asp + HA) − 2H2O]+, 643 [M + 2H − Val − (Asp + HA) − 2H2O]+, 453 [HA + Asp + Thr +
Arg + H − H2O]+, 404 [Ahp + Phe + MePhe + H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+, 297 [Asp + Thr +
Val + H − H2O]+, 243 [Ahp+Phe+H-H2O]+, 215 [Ahp+Phe+H-H2O-CO]+, 134 MePhe immonium ion, 120 Phe
immonium ion, 70-Arg; Figure S8: Chemical structure (A) and product ion mass spectra of cyanopeptolin CP978
[Thr+Arg+Ahp+Phe+MeTyr+Val]Asp+BA with precursor ion [M+H]+ at m/z 979. The spectra were recorded with
application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to the following
fragments: 961 [M + H − H2O]+, 933 [M + H − H2O − CO]+, 844 [M + H − Val − 2H2O]+, 794 [M + 2H − (Asp +
BA)]+, 776 [M + 2H − (Asp + BA) − H2O]+, 758 [M + 2H − (Asp + BA) − 2H2O]+, 659 [M + 2H − Val − (Asp
+ BA) − 2H2O]+, 425 [BA + Asp + Thr + Arg + H − H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 338 [Arg
+ Thr + Val + H − H2O]+, 308 [Phe(−N) + MeTyr + H]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H −
H2O − CO]+, 150 MeTyr immonium ion, 120 Phe immonium ion, 70-Arg; Figure S9: Chemical structure (A) and
product ion mass spectra of cyanopeptolin CP1027 [Thr+Tyr+Ahp+Phe+MeHty+Val]Asp+HA with precursor
ion [M+H-H2O]+ at m/z 1010. The spectra were recorded with application of QTOF (B) and QTRAP (C) mass
spectrometers. The mass signals were assigned to the following fragments: 992 [M + H − 2H2O]+, 982 [M + H −
H2O − CO]+, 964 [M + H − 2H2O − CO]+, 911 [M + H − Val − H2O]+, 893 [M + H − Val − 2H2O]+, 819 [M + H
−MeHty − H2O]+, 797 [M + 2H – (Asp + HA) − H2O]+, 779 [M + 2H − (Asp + HA) − 2H2O]+, 751 [M + 2H
− (Asp + HA) − 2H2O − CO]+, 702[M + H − (Val + MeHty) − H2O]+, 674 [M + H − (Val + MeHty) − H2O −
CO]+, 460 [M + H − (Val + MeHty + Phe + Ahp) − H2O]+, 442 [M + H − (Val + MeHty + Phe + Ahp) − 2H2O]+,
434 [Ahp + Phe + MeHty +H − H2O]+, 322 [Phe(−N) + MeHty + H]+, 297 [Asp + Thr+ Val +H − H2O]+, 243
[Ahp +Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 164 MeHty immonium ion, 136 Tyr immonium
ion, 120 Phe immonium ion; Figure S10: Chemical structure (A) and product ion mass spectra of cyanopeptolin
CP1013 [Thr+Tyr+Ahp+Phe+MeTyr+Val]Asp+HA with precursor ion [M+H-H2O]+ at m/z 996. The spectra were
recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to
the following fragments: 978 [M + H − 2H2O]+, 968 [M + H − H2O − CO]+, 897 [M + H − Val − H2O]+, 879 [M +
H − Val − 2H2O]+, 819 [M + H −MeTyr − H2O]+, 783 [M + 2H − (Asp + HA) − H2O]+, 765 [M + 2H − (Asp +
HA) − 2H2O]+, 736 [M + H − (Asp + HA) − 2H2O − CO]+, 720 [M + H − (Val + MeTyr) − H2O]+, 702 [M + H −
(Val + MeTyr)− 2H2O]+, 666 [M + 2H− Val− (Asp + HA)− 2H2O]+, 460 [M + H− (Val + MeTyr + Phe + Ahp)−
H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 432 [M + H − (Val + MeTyr + Phe + Ahp) − H2O − CO]+, 414 [HA
+ Asp + Thr + Val + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe+ H −
H2O − CO]+, 150 MeTyr immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion; Figure S11. Chemical
structure (A) and product ion mass spectra of cyanopeptolin CP999 [Thr+Tyr+Ahp+Phe+MeHty+Val]Asp+BA
with precursor ion [M+H-H2O]+ at m/z 982. The spectra were recorded with application of QTOF (B) and QTRAP
(C) mass spectrometers. The mass signals were assigned to the following fragments: 964 [M + H − 2H2O]+, 954
[M + H − H2O − CO]+, 883 [M + H − Val − H2O]+, 865 [M + H − Val − 2H2O]+, 797 [M + 2H − (Asp + BA) −
H2O]+, 779 [M + 2H − (Asp + BA) − 2H2O]+, 751 [M + 2H − (Asp + BA) − 2H2O − CO]+, 692 [M + H − (Val +
MeHty) − H2O]+, 674 [M + H − (Val + MeHty) − 2H2O]+, 698 [M + 2H − Val − (Asp + BA) − H2O]+, 680 [M +
2H − Val − (Asp + BA) − 2H2O]+, 646 [M + H − (Val + MeHty) − 2H2O − CO]+, 434 [Ahp + Phe + MeHty + H
− H2O]+, 432 [M + H − (Val + MeHty + Phe + Ahp) − H2O]+, 386 [BA + Asp + Thr + Val + H]+, 322 [Phe(−N) +
MeHty + H]+, 269 [Asp + Thr + Val + H − H2O − CO]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H −
H2O − CO]+, 164 MeHty immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion; Figure S12. Chemical
structure (A) and product ion mass spectra of cyanopeptolin CP969 [Thr+Tyr+Ahp+Phe+MePhe+Val]Asp+BA
with precursor ion [M + H − H2O]+ at m/z 952. The spectra were recorded with application of QTOF (B) and
QTRAP (C) mass spectrometers. The mass signals were assigned to the following fragments: 934 [M + H −
2H2O]+, 924 [M + H − H2O − CO]+, 853 [M + H − Val − H2O]+, 835 [M + H − Val − 2H2O]+, 791 [M + H −
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MePhe − H2O]+, 767 [M + 2H − (Asp + BA) − H2O]+, 749 [M + 2H − (Asp + BA) − 2H2O]+, 692 [M + H −
(Val + MePhe) − H2O]+, 674 [M + H − (Val + MePhe) − 2H2O]+, 432 [M + H − (Val + MePhe + Phe + Ahp) −
H2O]+, 414 [M + H − (Val + MePhe + Phe + Ahp) − 2H2O]+, 404 [Ahp + Phe + MePhe + H − H2O]+, 386 [BA +
Asp + Thr + Val + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H −
H2O − CO]+, 134 MePhe immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion; Figure S13. 1H-NMR
Spectrum of cyanopeptolin CP985 in DMSO-d6; Figure S14. HSQC Spectrum of cyanopeptolin CP985 in DMSO-d6;
Figure S15a. HMBC Spectrum of cyanopeptolin CP985 in DMSO-d6; Figure S15b. Detailed NH−C=O region of
the HMBC spectrum of cyanopeptolin CP985; Figure S15c. Detailed aromatic region of the HMBC spectrum of
cyanopeptolin CP985; Figure S16. COSY Spectrum of cyanopeptolin CP985 in DMSO-d6; Figure S17a. TOCSY
Spectrum of cyanopeptolin CP985 in DMSO-d6; Figure S17b. Amino acid spin systems in the diagnostic region of
the TOCSY spectrum of cyanopeptolin CP985; Figure S18a. ROESY Spectrum of cyanopeptolin CP985 in DMSO-d6;
Figure S18b. Overlaid fragments of TOCSY (green) and ROESY (red) spectra of cyanopeptolin CP985; Figure S19.
1H-NMR Spectrum of cyanopeptolin CP962 in DMSO-d6; Figure S20. HSQC Spectrum of cyanopeptolin CP962 in
DMSO-d6; Figure S21a. HMBC Spectrum of cyanopeptolin CP962 in DMSO-d6; Figure S21b. Detailed NH–C=O
region of the HMBC spectrum of cyanopeptolin CP962; Figure S21c. Detailed aromatic region of the HMBC
spectrum of cyanopeptolin CP962; Figure S22. COSY Spectrum of cyanopeptolin CP962 in DMSO-d6; Figure S23a.
TOCSY Spectrum of cyanopeptolin CP962 in DMSO-d6; Figure S23b. Amino acid spin systems in the diagnostic
region of the TOCSY spectrum of cyanopeptolin CP962; Figure S24a. ROESY Spectrum of cyanopeptolin CP962 in
DMSO-d6; Figure S24b. Overlaid fragments of TOCSY (green) and ROESY (red) spectra of cyanopeptolin CP962.
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Figure S1. LC-MS/MS chromatogram of cyjanopeptolins (CPs) in crude extract from Nostoc edaphicum 
CCNP1411 (A) and chromatograms of isolated peptides: CP962 (B) and CP985 (C). 
  
     
Figure S2. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP1049 
[Thr+Arg+Ahp+Phe+MeHty+Val]Asp+OA with precursor ion [M + H]+ at m/z 1049. The spectra were recorded 
with application of a hybride quadrupole/time-of-flight mass spectrometer (QTOF) (B) and a hybride triple 
quadrupole/linear ion trap mass spectrometer (QTRAP) (C). The mass signals were assigned to the following 
fragments: 1031 [M + H − H2O]+, 1003 [M + H − H2O − CO]+, 932 [M + H − Val − H2O]+, 914 [M + H − Val − 
2H2O]+, 808 [M + 2H − (Asp + OA)]+, 790 [M + 2H − (Asp + OA) − H2O]+, 772 [M + 2H − (Asp + OA) − 2H2O]+, 741 
[M + H − (Val + MeHty) − H2O]+, 673 [M + 2H − Val − (Asp + OA) − 2H2O]+, 481 [OA+Asp + Thr + Arg + H − 
H2O]+, 434 [Ahp + Phe + MeHty + H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+, 322 [Phe(−N) + MeHty + H]+, 297 
[Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 164 MeHty 
immonium ion, 120 Phe immonium ion, 70-Arg. 
  
 
Figure S3. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP1020 
[Thr+Arg+Ahp+Phe+MeHty+Val]Asp+HA with precursor ion [M+H]+ at m/z 1021. The spectra were recorded 
with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to the 
following fragments: 1003 [M+H-H2O]+, 975 [M+H-H2O-CO]+, 886 [M+H-Val-2H2O]+, 808 [M+2H-(Asp+HA)]+,  
790 [M+2H-(Asp+HA)-H2O]+, 772 [M+2H-(Asp+OA)-2H2O]+, 713 [M+H-(Val+MeHty)-H2O]+,  
691 [M+2H-Val-(Asp+HA)-H2O]+, 673 [M+2H-Val-(Asp+HA)-2H2O]+, 453 [HA+Asp+Thr+Arg+H-H2O]+,  
434 [Ahp+Phe+MeHty+H-H2O]+, 338 [Arg+Thr+Val+H-H2O]+, 322 [Phe(-N)+MeHty+H]+, 297 [Asp+Thr+Val+H-
H2O]+, 243 [Ahp+Phe+H-H2O]+, 215 [Ahp+Phe+H-H2O-CO]+, 164 MeHty immonium ion, 120 Phe immonium 
ion, 70-Arg. 
  
 
Figure S4. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP1018 
[Thr+Arg+Ahp+Phe+MePhe+Val]Asp+OA with precursor ion [M+H]+ at m/z 1019. The spectra were recorded 
with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to the 
following fragments: 1001 [M + H − H2O]+, 983 [M + H − 2H2O]+, 973 [M + H − H2O − CO]+, 902 [M + H − Val − 
H2O]+, 884 [M + H − Val − 2H2O]+, 778 [M + 2H − (Asp + OA)]+, 760 [M + 2H -− (Asp + OA) − H2O]+, 742 [M + 2H 
− (Asp + OA) − 2H2O]+, 661 [M + 2H − Val − (Asp+OA) − H2O]+, 643 [M + 2H − Val − (Asp + OA) − 2H2O]+, 481 
[OA + Asp + Thr + Arg + H - H2O]+, 404 [Ahp + Phe + MePhe + H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+, 308 
[Phe(-N) + MeTyr + H]+, 297 [Asp + Thr + Val + H - H2O]+, 243 [Ahp + Phe + H - H2O]+, 215 [Ahp + Phe + H - 
H2O − CO]+, 134 MePhe immonium ion, 120 Phe immonium ion, 70-Arg. 
  
 
Figure S5. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP1006 
[Thr+Arg+Ahp+Phe+MeTyr+Val]Asp+HA with precursor ion [M + H]+ at m/z 1007. The spectra were recorded 
with application of QTOF (B) and QTRAP (A) mass spectrometers. The mass signals were assigned to the 
following fragments: 989 [M + H − H2O]+, 961 [M + H − H2O − CO]+, 872 [M + H − Val − 2H2O]+, 794 [M + 2H − 
(Asp + HA)]+, 776 [M + 2H − (Asp + HA) − H2O]+, 766 [ M + 2H − (Asp + HA) − CO]+, 758 [M + 2H − (Asp + HA) 
− 2H2O]+, 713 [M + H − (Val + MeHTyr) − H2O]+, 659 [M + 2H − Val − (Asp + HA) − 2H2O]+, 453 [HA + Asp + Thr 
+ Arg + H − H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 338 [Arg + Thr + Val + H − H2O]+, 308 [Phe(−N) + 
MeTyr + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 
150 MeTyr immonium ion, 120 Phe immonium ion, 70-Arg. 
  
 
Figure S6. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP992 
[Thr+Arg+Ahp+Phe+MeHty+Val]Asp+BA with precursor ion [M + H]+ at m/z 993. The spectra were recorded 
with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to the 
following fragments: 975 [M + H − H2O]+, 947 [M + H − H2O − CO]+, 858 [M + H − Val −-2H2O]+, 808 [M + 2H 
−  (Asp + BA)]+, 790 [M + 2H − (Asp + BA) − H2O]+, 772 [M + 2H − (Asp + BA) − 2H2O]+, 673 [M + 2H − Val − 
(Asp + BA) − 2H2O]+, 434 [Ahp + Phe + MeHty + H − H2O]+, 425 [BA + Asp + Thr + Arg + H − H2O]+, 338 [Arg 
+ Thr + Val + H − H2O]+, 322 [Phe(−N) + MeHty + H]+, 243 [Ahp + Ph + H − H2O]+, 215 [Ahp + Phe + H − H2O − 
CO]+, 164 MeHty immonium ion, 120 Phe immonium ion, 70-Arg. 
  
 
Figure S7. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP990 [Thr+Arg+Ahp+Phe 
+MePhe+Val]Asp+HA with precursor ion [M + H]+ at m/z 991. The spectra were recorded with application of 
QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to the following fragments: 973 
[M + H − H2O]+, 945 [M + H − H2O − CO]+, 856 [M + H − Val − 2H2O]+, 778 [M + 2H − (Asp + HA)]+, 760 [M + 
2H − (Asp + HA) − H2O]+, 750 [M + 2H − (Asp + HA) − CO]+, 742 [M + 2H-(Asp + HA) − 2H2O]+, 643 [M + 2H − 
Val − (Asp + HA) − 2H2O]+, 453 [HA + Asp + Thr + Arg + H − H2O]+, 404 [Ahp + Phe + MePhe + H − H2O]+, 338 
[Arg + Thr + Val + H − H2O]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp+Phe+H-H2O]+, 215 [Ahp+Phe+H-
H2O-CO]+, 134 MePhe immonium ion, 120 Phe immonium ion, 70-Arg. 
  
 
Figure S8. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP978 
[Thr+Arg+Ahp+Phe+MeTyr+Val]Asp+BA with precursor ion [M+H]+ at m/z 979. The spectra were recorded 
with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to the 
following fragments: 961 [M + H − H2O]+, 933 [M + H − H2O − CO]+, 844 [M + H − Val − 2H2O]+, 794 [M + 2H − 
(Asp + BA)]+, 776 [M + 2H − (Asp + BA) − H2O]+, 758 [M + 2H − (Asp + BA) − 2H2O]+, 659 [M + 2H − Val − (Asp 
+ BA) − 2H2O]+, 425 [BA + Asp + Thr + Arg + H − H2O]+, 420 [Ahp + Phe + MeTyr + H − H2O]+, 338 [Arg + Thr + 
Val + H − H2O]+, 308 [Phe(−N) + MeTyr + H]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 
150 MeTyr immonium ion, 120 Phe immonium ion, 70-Arg. 
  
 
Figure S9. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP1027 
[Thr+Tyr+Ahp+Phe+MeHty+Val]Asp+HA with precursor ion [M+H-H2O]+ at m/z 1010. The spectra were 
recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to 
the following fragments: 992 [M + H − 2H2O]+, 982 [M + H − H2O − CO]+, 964 [M + H − 2H2O − CO]+, 911 [M + 
H − Val − H2O]+, 893 [M + H − Val − 2H2O]+, 819 [M + H − MeHty − H2O]+, 797 [M + 2H – (Asp + HA) − H2O]+, 
779 [M + 2H − (Asp + HA) − 2H2O]+, 751 [M + 2H − (Asp + HA) − 2H2O − CO]+, 702[M + H − (Val + MeHty) − 
H2O]+, 674 [M + H − (Val + MeHty) − H2O − CO]+, 460 [M + H − (Val + MeHty + Phe + Ahp) − H2O]+, 442 [M + 
H − (Val + MeHty + Phe + Ahp) − 2H2O]+, 434 [Ahp + Phe + MeHty +H − H2O]+, 322 [Phe(−N) + MeHty + H]+, 
297 [Asp + Thr+ Val +H − H2O]+, 243 [Ahp +Phe + H − H2O]+, 215 [Ahp + Phe + H − H2O -− CO]+, 164 MeHty 
immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion. 
  
 
Figure S10. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP1013 
[Thr+Tyr+Ahp+Phe+MeTyr+Val]Asp+HA with precursor ion [M+H-H2O]+ at m/z 996. The spectra were 
recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to 
the following fragments: 978 [M + H − 2H2O]+, 968 [M + H − H2O − CO]+, 897 [M + H − Val − H2O]+, 879 [M + H 
− Val − 2H2O]+, 819 [M + H − MeTyr − H2O]+, 783 [M + 2H − (Asp + HA) − H2O]+, 765 [M + 2H − (Asp + HA) − 
2H2O]+, 736 [M + H − (Asp + HA) − 2H2O − CO]+, 720 [M + H − (Val + MeTyr) − H2O]+, 702 [M + H − (Val + 
MeTyr) − 2H2O]+, 666 [M + 2H − Val − (Asp + HA) − 2H2O]+, 460 [M + H − (Val + MeTyr + Phe + Ahp) − H2O]+, 
420 [Ahp + Phe + MeTyr + H − H2O]+, 432 [M + H − (Val + MeTyr + Phe + Ahp) − H2O − CO]+, 414 [HA + Asp + 
Thr + Val + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe+ H − H2O − 
CO]+, 150 MeTyr immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion. 
  
 
Figure S11. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP999 
[Thr+Tyr+Ahp+Phe+MeHty+Val]Asp+BA with precursor ion [M+H-H2O]+ at m/z 982. The spectra were 
recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to 
the following fragments: 964 [M + H − 2H2O]+, 954 [M + H − H2O − CO]+, 883 [M + H − Val − H2O]+, 865 [M + H 
− Val − 2H2O]+, 797 [M + 2H − (Asp + BA) − H2O]+, 779 [M + 2H − (Asp + BA) − 2H2O]+, 751 [M + 2H − (Asp + 
BA) − 2H2O − CO]+, 692 [M + H − (Val + MeHty) − H2O]+, 674 [M + H − (Val + MeHty) − 2H2O]+, 698 [M + 2H − 
Val − (Asp + BA) − H2O]+, 680 [M + 2H − Val − (Asp + BA) − 2H2O]+, 646 [M + H − (Val + MeHty) − 2H2O − 
CO]+, 434 [Ahp + Phe + MeHty + H − H2O]+, 432 [M + H − (Val + MeHty + Phe + Ahp) − H2O]+, 386 [BA + Asp + 
Thr + Val + H]+, 322 [Phe(−N) + MeHty + H]+, 269 [Asp + Thr + Val + H − H2O − CO]+, 243 [Ahp + Phe + H − 
H2O]+, 215 [Ahp + Phe + H − H2O − CO]+, 164 MeHty immonium ion, 136 Tyr immonium ion, 120 Phe 
immonium ion. 
 
 
 
Figure S12. Chemical structure (A) and product ion mass spectra of cyanopeptolin CP969 
[Thr+Tyr+Ahp+Phe+MePhe+Val]Asp+BA with precursor ion [M + H − H2O]+ at m/z 952. The spectra were 
recorded with application of QTOF (B) and QTRAP (C) mass spectrometers. The mass signals were assigned to 
the following fragments: 934 [M + H − 2H2O]+, 924 [M + H − H2O − CO]+, 853 [M + H − Val − H2O]+, 835 [M + H 
− Val − 2H2O]+, 791 [M + H − MePhe − H2O]+, 767 [M + 2H − (Asp + BA) − H2O]+, 749 [M + 2H − (Asp + BA) − 
2H2O]+, 692 [M + H − (Val + MePhe) − H2O]+, 674 [M + H − (Val + MePhe) − 2H2O]+, 432 [M + H − (Val + MePhe 
+ Phe + Ahp) − H2O]+, 414 [M + H − (Val + MePhe + Phe + Ahp) − 2H2O]+, 404 [Ahp + Phe + MePhe + H − H2O]+, 
386 [BA + Asp + Thr + Val + H]+, 297 [Asp + Thr + Val + H − H2O]+, 243 [Ahp + Phe + H − H2O]+, 215 [Ahp + Phe 
+ H − H2O − CO]+, 134 MePhe immonium ion, 136 Tyr immonium ion, 120 Phe immonium ion. 
 Figure S13. 1H NMR Spectrum of cyanopeptolin CP985 in DMSO-d6. 
 Figure S14. HSQC Spectrum of cyanopeptolin CP985 in DMSO-d6. 
 Figure S15a. HMBC Spectrum of cyanopeptolin CP985 in DMSO-d6. 
 Figure S15b. Detailed NH – C=O region of the HMBC spectrum of cyanopeptolin CP985. 
 Figure S15c. Detailed aromatic region of the HMBC spectrum of cyanopeptolin CP985. 
 Figure S16. COSY Spectrum of cyanopeptolin CP985 in DMSO-d6. 
 Figure S17a. TOCSY Spectrum of cyanopeptolin CP985 in DMSO-d6. 
 Figure S17b. Amino acid spin systems in the diagnostic region of the TOCSY spectrum of cyanopeptolin CP985. 
 Figure S18a. ROESY Spectrum of cyanopeptolin CP985 in DMSO-d6. 
 Figure S18b. Overlaid fragments of TOCSY (green) and ROESY (red) spectra of cyanopeptolin CP985. 
 Figure S19. 1H NMR Spectrum of cyanopeptolin CP962 in DMSO-d6. 
 Figure S20. HSQC Spectrum of cyanopeptolin CP962 in DMSO-d6. 
 Figure S21a. HMBC Spectrum of cyanopeptolin CP962 in DMSO-d6. 
 Figure S21b. Detailed NH – C=O region of the HMBC spectrum of cyanopeptolin CP962. 
 Figure S21c. Detailed aromatic region of the HMBC spectrum of cyanopeptolin CP962. 
 Figure S22. COSY Spectrum of cyanopeptolin CP962 in DMSO-d6. 
 Figure S23a. TOCSY Spectrum of cyanopeptolin CP962 in DMSO-d6. 
 Figure S23b. Amino acid spin systems in the diagnostic region of the TOCSY spectrum of cyanopeptolin CP962. 
 Figure S24a. ROESY Spectrum of cyanopeptolin CP962 in DMSO-d6. 
 Figure S24b. Overlaid fragments of TOCSY (green) and ROESY (red) spectra of cyanopeptolin CP962. 
